contact us
subTop TechOffers
  • diganostic SurrogateMarkerPatients with Type 2 Diabetes (T2DM) have a 2-fold greater risk of cardiovascular disease (CVD).
  • Identifying predictors of CVD events will aid early diagnosis to better risk stratification and improve clinical management.

  • Current clinical practice includes invasive and time consuming tests to determine the toe brachial index at time of treatment.

  • Endothelial dysfunction is an important marker of predictors of CVD events.

  • There is a need to measure maximum distensibility in the radial artery in a non-invasive manner.

 

Market Impact
  • According to a market report, the CVD market is projected to increase at a CAGR of 9.7% by 2020.
  • The American Heart Association considers diabetes to be one of the seven major controllable risk factors for cardiovascular disease.
  • Singapore has the second-highest proportion of diabetics among developed nations, according to a report in 2015, by the International Diabetes Federation (IDF).

 

Technology Description
  • The technology utilises a prototype device to measure vessel distensibility quantifying magnetic flux disturbances when blood flows through a uniform magnetic field.
  • A mathematical model is developed based on the concept of hemodynamic modulation to quantify the maximum possible dilation using arterial form waveforms.
  • Waveforms are measured for 5 minutes and compared to a baseline waveform to determine radial artery maximum distensibility index (RA-MDI).
  • Device wraps around the wrist and has the capability to detect radial artery pulse amplitude.

 

Development Status
  • With NHIC funding, repeatability, reproducibility, inter-and intra-operator reliability of the prototype device was established in a healthy volunteer study.
  • Subsequently, clinical feasibility study in a small cohort of patients showed consistency and repeatability amongst diabetic patients with measurements taken at different time
  • Significant correlations of RA-MDI were seen with traditional CV risk scores such as Framingham risk score.

Current IP Position:

(1) PCT/SG2006/000409 (granted) (2) PCT/SG2007/000180 (granted) (3) SG 2017 provisional

 

Future Progress

Team aims to use the device in primary care to risk stratify patients for intensive management and to guide treatment.

Currently seeking commercial partners for IP licensing OR Collaborative technology development for further development

 

 

Dr Rinkoo Dalan / National Healthcare Group

 

targetGroup_clinicianInnovators
targetGroup_ResearchAdministrator
targetGroup_IndustryPartner
targetGroup_Investor